Abstract 513MO
Background
Clinical observations indicate a higher prevalence of psychiatric disorders, in particular neurodevelopmental disorders, among testicular germ cell cancer (TGCC) patients. Our aim was to investigate if history of specific psychiatric disorders is associated with increased risk of TGCC and/or increased mortality.
Methods
We conducted a nested case-control study including 6,250 TGCC patients diagnosed 1992-2014, individually matched to 62,500 controls. Using conditional logistic regression, we calculated odds ratios (ORs) and 95% confidence intervals (CIs) for the association between history of psychiatric diagnoses and TGCC risk. Among the cases only, we used a cohort study design and Cox regression to calculate hazard ratios (HRs) with 95% CIs of the association between psychiatric diagnosis and all-cause and TGCC-specific mortality.
Results
History of a neurodevelopmental disorder (i.e., attention deficit hyperactivity disorder, autism spectrum disorder and intellectual disabilities) was associated with an increased risk of seminoma (OR 1.54; 95% CI 1.09-2.19). Seminoma patients with neurodevelopmental disorders were also younger (34 versus 38 years, p=0.004) and more often presented with stage IV disease (5.4% versus 1.2%) than those without. A decreased risk of seminoma was seen for patients with psychotic disorders (OR 0.62; 95% CI 0.40-0.96). Psychiatric history overall was not associated with TGCC. Patient history of any psychiatric disorder was associated with an increased all-cause mortality (HR 2.91; 95% CI 2.11-4.02) and an increased TGCC-specific mortality (HR 1.79; 95% CI 1.04-3.08).
Conclusions
We report, for the first time, an association between neurodevelopmental disorders and testicular seminoma. Furthermore, we found an increased TGCC-specific mortality for TGCC-patients with psychiatric disorders.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Uppsala University, Research group Ingrid Glimelius.
Funding
Swedish Cancer Society (CAN 19 0123 Pj).
Disclosure
A. Pettersson: Financial Interests, Personal, Other, Honoraria: Capio St. Göran; Financial Interests, Personal, Other, Honararia: Astellas Pharma; Financial Interests, Personal, Other, Honoraria: Mediahuset i Göteborg; Financial Interests, Personal, Other, Advisor: Janssen-Cilag; Financial Interests, Personal, Other, Grants: Merck & Co.; Financial Interests, Personal, Other, CEO and Co-Founder: Levo Prevention AB. I. Glimelius: Financial Interests, Institutional, Other, I participate as Scientific Board on an Educational Event: Janssen-Cilag; Financial Interests, Personal, Other, I participate in a Real-World Initiative to Study Register-Based Data Supported by: Takeda; Financial Interests, Personal, Other, Safety Board for Evaluation of Side-Effects from the Viral Vector Developed within the Company: Lokon Pharma. All other authors have declared no conflicts of interest.
Resources from the same session
1449MO - Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study
Presenter: Camillo Guglielmo Porta
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1450MO - Efficacy of a tailored approach with nivolumab and nivolumab/ipilimumab as immunotherapeutic boost in metastatic renal cell carcinoma: Final results of TITAN-RCC
Presenter: Marc-Oliver Grimm
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 1449MO and 1450MO
Presenter: Kate Young
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Slides
Webcast
LBA75 - RACE IT: A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urothelial carcinoma of the bladder (AB 65/18) – first results
Presenter: Sebastian Schmid
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1733MO - First results from BladderPath: A randomised trial of MRI versus cystoscopic staging for newly diagnosed bladder cancer
Presenter: Nicholas James
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1734MO - Hypoxic bladder cancers have a poorer outcome following hypofractionated vs conventionally fractionated radiotherapy in the BC2001 and BCON randomised trials
Presenter: Tim Smith
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA75, 1733MO and 1734MO
Presenter: Joaquim Bellmunt
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Slides
Webcast
1310MO - Neoadjuvant platinum-based chemotherapy (NAPC) for metastatic penile squamous cell carcinoma (PSCC): An international, multicenter, real-world study
Presenter: Jad Chahoud
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
512MO - Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: An analysis of the IGCCCG Update database
Presenter: Silke Gillessen
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 1310MO, 512MO and 513MO
Presenter: Aly-Khan Lalani
Session: Mini Oral session 1: GU tumours, non-prostate
Resources:
Slides
Webcast